CA2467434C - Reversible mhc multimer staining for functional purification of antigen-specific t cells - Google Patents

Reversible mhc multimer staining for functional purification of antigen-specific t cells Download PDF

Info

Publication number
CA2467434C
CA2467434C CA2467434A CA2467434A CA2467434C CA 2467434 C CA2467434 C CA 2467434C CA 2467434 A CA2467434 A CA 2467434A CA 2467434 A CA2467434 A CA 2467434A CA 2467434 C CA2467434 C CA 2467434C
Authority
CA
Canada
Prior art keywords
binding
cell
cells
partner
receptor molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2467434A
Other languages
English (en)
French (fr)
Other versions
CA2467434A1 (en
Inventor
Dirk H. Busch
Hermann Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
IBA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IBA GmbH filed Critical IBA GmbH
Publication of CA2467434A1 publication Critical patent/CA2467434A1/en
Application granted granted Critical
Publication of CA2467434C publication Critical patent/CA2467434C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Ecology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA2467434A 2000-12-28 2001-12-28 Reversible mhc multimer staining for functional purification of antigen-specific t cells Expired - Lifetime CA2467434C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00128634A EP1227321A1 (en) 2000-12-28 2000-12-28 Reversible MHC multimer staining for functional purification of antigen-specific T cells
EP00128634.3 2000-12-28
PCT/EP2001/015353 WO2002054065A2 (en) 2000-12-28 2001-12-28 Reversible mhc multimer staining for functional purification of antigen-specific t cells

Publications (2)

Publication Number Publication Date
CA2467434A1 CA2467434A1 (en) 2002-07-11
CA2467434C true CA2467434C (en) 2013-02-19

Family

ID=8170850

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2467434A Expired - Lifetime CA2467434C (en) 2000-12-28 2001-12-28 Reversible mhc multimer staining for functional purification of antigen-specific t cells

Country Status (5)

Country Link
US (2) US7776562B2 (enExample)
EP (2) EP1227321A1 (enExample)
JP (1) JP4416400B2 (enExample)
CA (1) CA2467434C (enExample)
WO (1) WO2002054065A2 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
EP1878744A1 (en) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
US20080255004A1 (en) * 2006-11-15 2008-10-16 Invitrogen Dynal As Methods of reversibly binding a biotin compound to a support
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
JP5686098B2 (ja) * 2009-09-17 2015-03-18 Jsr株式会社 アビジンとビオチン誘導体の解離方法及び解離剤
EP3144673B1 (en) 2010-05-06 2019-07-10 Adaptive Biotechnologies Corporation Monitoring lymphoid neoplasm status using clonotype profiles
US9345748B2 (en) 2010-09-21 2016-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SSX-2 T cell receptors and related materials and methods of use
US10023657B2 (en) 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
ES2682750T5 (en) 2011-07-18 2025-02-04 Iba Lifesciences Gmbh Method of reversibly staining a target cell
WO2013056090A1 (en) * 2011-10-12 2013-04-18 University Of Connecticut Affinity-based materials for the non-destructive separation and recovery of cells
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
CN102662054B (zh) * 2012-05-10 2014-08-13 东南大学 一种同步检测特异性胸腺依赖性淋巴细胞数量和功能的方法
EP2920204B1 (en) 2012-11-16 2019-09-18 IBA GmbH Streptavidin muteins and methods of using them
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
US9970849B2 (en) 2014-01-21 2018-05-15 Stemcell Technologies Inc. Method for separating target entities from a sample using a composition of mono-specific tetrameric antibody complexes coupled to a surface
RS62471B1 (sr) 2014-04-16 2021-11-30 Juno Therapeutics Gmbh Metode, kompleti i uređaji za proširenje populacije ćelija
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
CN106662584B (zh) 2014-04-30 2020-05-05 Iba股份有限公司 分离靶细胞的方法
EP3037820A1 (en) 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Cell detection methods and reagents having a releasable labelling moiety
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
JP6657721B2 (ja) 2015-09-30 2020-03-04 ソニー株式会社 細胞の分析方法、細胞分析用チップ、細胞分析用試薬、細胞分析用キット及び細胞分析用装置
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
KR102908806B1 (ko) * 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
WO2017180420A1 (en) 2016-04-11 2017-10-19 Board Of Regents, The University Of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
WO2018001985A1 (en) 2016-06-28 2018-01-04 Technische Universitaet Muenchen Combination of reversible and irreversible cell labeling for analizing receptor-ligand koff rate
TW202332461A (zh) 2016-08-11 2023-08-16 荷蘭商凱特製藥歐洲公司 製造和使用可溶性主要組織相容性複合體（ｍｈｃ）分子類之方法
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP3336545A1 (en) 2016-12-13 2018-06-20 Miltenyi Biotec GmbH Reversible labeling of antigens in biological specimens
EP3336546B1 (en) 2016-12-13 2020-07-01 Miltenyi Biotec B.V. & Co. KG Reversible cell labelling with conjugates having two releasable binding sites
EP3571221A2 (en) 2017-01-20 2019-11-27 Juno Therapeutics GmbH Cell surface conjugates and related cell compositions and methods
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
EP4549554A3 (en) 2017-07-29 2025-08-06 Juno Therapeutics, Inc. Reagents for expanding cells expressing recombinant receptors
EP3489684B1 (en) 2017-11-27 2024-06-26 Miltenyi Biotec B.V. & Co. KG Method for photobleaching stained cells
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
CN116148467B (zh) * 2017-12-12 2026-05-26 清华大学 检测翻译后修饰蛋白质与其配体间相互作用的成套试剂
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
US20210246189A1 (en) 2018-09-03 2021-08-12 Technische Universitaet Muenchen A double peptide tag combining reversibility and flexible functionalization
JP7504891B2 (ja) 2018-09-11 2024-06-24 ジュノー セラピューティクス インコーポレイテッド 操作された細胞組成物のマススペクトロメトリー分析のための方法
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
US20210393691A1 (en) 2018-11-06 2021-12-23 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
KR102922115B1 (ko) 2019-04-09 2026-02-04 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도
US12436151B2 (en) 2019-04-12 2025-10-07 Miltenyi Biotec B.V. & Co. KG Conjugates having an enzymmatically releasable detection moiety and a barcode moiety
CA3140873A1 (en) 2019-05-17 2020-11-26 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
CN113966394A (zh) 2019-05-28 2022-01-21 美天施生物科技有限两合公司 产生遗传修饰的t细胞的方法
US20220228101A1 (en) 2019-06-07 2022-07-21 Juno Therapeutics, Inc. Automated t cell culture
CA3294689A1 (en) 2019-06-26 2026-03-02 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
US12653809B2 (en) 2019-07-30 2026-06-16 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition
CN114600172A (zh) 2019-08-30 2022-06-07 朱诺治疗学股份有限公司 用于将细胞分类的机器学习方法
WO2021047804A1 (en) 2019-09-11 2021-03-18 Miltenyi Biotec B.V. & Co. KG In vitro method for transduction of t cells in the presence of malignant cells
MX2022005145A (es) 2019-10-30 2022-06-29 Juno Therapeutics Gmbh Dispositivos de estimulación y/o selección celular y método de uso.
WO2021122185A1 (en) 2019-12-20 2021-06-24 Miltenyi Biotec B.V. & Co. KG Reversible cell detection via mhc with conjugates having an enzymatically cleavable detection moiety
US20230090117A1 (en) 2020-01-28 2023-03-23 Juno Therapeutics, Inc. Methods for t cell transduction
AU2021213439B2 (en) 2020-01-31 2023-01-05 Cell.Copedia GmbH Methods of isolating a biological entity
CA3169672A1 (en) 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
JP2023519099A (ja) 2020-02-12 2023-05-10 ジュノー セラピューティクス インコーポレイテッド Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
EP3916393B1 (en) 2020-05-27 2023-01-25 Miltenyi Biotec B.V. & Co. KG Method for detection of cells by repetitive staining and destaining
WO2022043023A1 (en) 2020-08-27 2022-03-03 Miltenyi Biotec B.V. & Co. KG Releasable reagents for cell separation
CN115997126B (zh) 2020-09-07 2025-11-28 美天施生物科技有限两合公司 具有可酶促释放的检测部分和条形码部分的缀合物
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
WO2023017115A1 (en) 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionation of cells based on a marker protein
EP4227423A1 (en) 2022-02-09 2023-08-16 Technische Universität München Means and methods for identifying high affinity t-cells
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
US20260232729A1 (en) 2023-02-03 2026-08-13 C3S2 Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2024182516A1 (en) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
EP4484441A1 (en) 2023-06-26 2025-01-01 Eberhard-Karls-Universität Tübingen Mhc-class i derived polypeptide
KR20260096851A (ko) 2023-10-18 2026-06-24 티큐 테라퓨틱스 게엠베하 세포 치료제 제조 방법 및 관련 키트와 장치

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948590A (en) * 1987-06-09 1990-08-14 Yale University Avidin or streptavidin conjugated liposomes
DE4237113B4 (de) * 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
US5595881A (en) * 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
WO1997011183A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
WO1997009068A2 (en) * 1995-09-01 1997-03-13 University Of Washington Interactive molecular conjugates
DE19641876B4 (de) * 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
US5985658A (en) * 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
FR2841905B1 (fr) * 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications

Also Published As

Publication number Publication date
US7776562B2 (en) 2010-08-17
US20110070605A1 (en) 2011-03-24
WO2002054065A2 (en) 2002-07-11
WO2002054065A3 (en) 2002-11-28
EP1346217B1 (en) 2020-10-21
US20040082012A1 (en) 2004-04-29
US8298782B2 (en) 2012-10-30
EP1227321A1 (en) 2002-07-31
CA2467434A1 (en) 2002-07-11
JP2004525354A (ja) 2004-08-19
EP1346217A2 (en) 2003-09-24
JP4416400B2 (ja) 2010-02-17

Similar Documents

Publication Publication Date Title
EP1346217B1 (en) Reversible mhc multimer staining for functional purification of antigen-specific t cells
US20220205984A1 (en) General Detection and Isolation of Specific Cells by Binding of Labeled Molecules
JP6310388B2 (ja) 標的細胞を可逆的に染色する方法
AU2016341533B2 (en) Methods for culturing cells and kits and apparatus for same
AU2002240818B2 (en) MHC molecule constructs and their uses for diagnosis and therapy
AU2022200527A1 (en) Methods, kits and apparatus for expanding a population of cells
US20150329617A1 (en) Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
KR20200019126A (ko) 올리고머 입자 시약 및 이의 사용 방법
WO2010037397A1 (en) Mhc multimers in cmv immune monitoring
Denkberg et al. Recombinant human single‐chain MHC‐peptide complexes made from E. coli by in vitro refolding: functional single‐chain MHC‐peptide complexes and tetramers with tumor associated antigens
WO2016166568A1 (en) Methods, kits and apparatus for expanding a population of cells
JP4976294B2 (ja) 細胞傷害性ｔ細胞エピトープペプチド及びその用途
Gillespie et al. HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand
WO2006016113A1 (en) Cellular tcr ligand assay method
KR20240130120A (ko) T 세포 수용체 및 이의 제조 방법과 용도
BR112018008061B1 (pt) Métodos para modulação de células t, artigo de fabricação para a purificação e modulação de células-alvo, e aparelhos

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20211229